There was no shortage of uncertainty and controversy around Vertex's (NASDAQ: VRTX )
phase 3 trials for its cystic fibrosis (or CF) combo therapy.
Bernstein analyst Geoffrey Porges was perhaps the most visible bear
recently, asserting on June 16 that "the probability of failure in this
trial is high". Now that Vertex has actually released the data, the
bears are licking their wounds – the results of the TRAFFIC and
TRANSPORT studies were not perfect, but a "B+" ought to be more than
enough to get FDA approval, leading to upwards of $5 billion in
incremental revenue.
Read more here:
A Big Step Forward for Vertex Pharmaceuticals, Inc
No comments:
Post a Comment